Canterbury Scientific’s 2011 surge in revenue earned the company a spot among the Technology Investment Network’s annual list of New Zealand’s Top 10 Hot Emerging Companies. A year on, it’s doubled in size, thanks in no small part to its cornerstone product, the HbA1c – a blood test used in the management of diabetes.
HbA1c is stable with a long life, easily transportable, and does not involve the use of diabetic patient blood, so no diabetes sufferers are put at risk in its manufacture – instead, it’s made from healthy blood samples in a test tube. This also allows for much larger production volumes.
The product is prized by global healthcare giants like Roche, Siemens and Beckman Coulter and relied on by thousands of people around the world to help manage their diabetes. It is available in both freeze dried and liquid form, and Canterbury Scientific can also customise variations of the product to meet specific needs.
Diabetes is tipped to rise to epidemic proportions in the future, and as as diagnostic technology advances, more doctors and diabetics will be able to conduct monitoring tests in house instead of waiting on clinical laboratories for results. The HbA1c control helps to standardise results between different laboratories and methods, and soon diabetics may even be able to conduct tests themselves.